Related Experiment Video
Updated: Jun 20, 2026
06:17
Expression and Purification of Virus-like Particles for Vaccination
Published on: June 2, 2016
22.5K
Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform
Flavia Chiuppesi1, Marcela d'Alincourt Salazar1, Heidi Contreras1
1Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte, CA, 91010, USA.
Nature Communications
|December 1, 2020
Summary
A novel vaccine platform using synthetic DNA efficiently creates modified vaccinia Ankara (MVA) vectors. These vectors rapidly produce a SARS-CoV-2 vaccine candidate, inducing strong immune responses in mice.
Area of Science:
- Virology
- Vaccinology
- Synthetic Biology
Background:
- Modified Vaccinia Ankara (MVA) is a versatile viral vector for vaccine development.
- Rapid response to emerging infectious diseases like SARS-CoV-2 is critical.
Purpose of the Study:
- To develop an efficient vaccine platform for generating recombinant MVA vectors using synthetic DNA.
- To create a synthetic MVA (sMVA) vector expressing SARS-CoV-2 antigens for a rapid vaccine candidate.
Main Methods:
- Construction of a three-plasmid system for MVA vector generation from synthetic DNA.
- Engineering sMVA vectors to co-express SARS-CoV-2 spike and nucleocapsid antigens.
- Immunization of mice with sMVA vectors and assessment of immune responses.
Main Results:
- Demonstrated efficient generation of recombinant MVA vectors from chemically synthesized DNA.
- Successfully produced sMVA vectors co-expressing key SARS-CoV-2 antigens.
- Mice immunized with sMVA vectors showed robust antigen-specific humoral and cellular immunity, including neutralizing antibodies.
Conclusions:
- The synthetic DNA-based platform enables efficient MVA vector generation.
- This platform facilitates the rapid development of multi-antigenic poxvirus-based vaccines.
- The developed sMVA vector is a promising SARS-CoV-2 vaccine candidate.
More Related Videos
Related Concept Videos
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
01:24Smallpox
Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.